These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 5791298)

  • 21. [Silent period in patients with Parkinson's disease treated with L-Dopa].
    Palao Sánchez A
    Arch Neurobiol (Madr); 1973; 36(1):47-56. PubMed ID: 4706780
    [No Abstract]   [Full Text] [Related]  

  • 22. [Personal experience in the treatment of Parkinson's disease with L-Dopa].
    Figuerido JA; De la Herrán J
    Rev Clin Esp; 1970 Dec; 119(6):555-62. PubMed ID: 5509794
    [No Abstract]   [Full Text] [Related]  

  • 23. Parkinson's disease treated with L-dopa. Three-year follow-up report.
    Mones RJ
    N Y State J Med; 1972 Nov; 72(22):2749-50. PubMed ID: 4510706
    [No Abstract]   [Full Text] [Related]  

  • 24. [Therapy of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor (Ro 4-4602). Course in 71 patients].
    Ferel D
    Schweiz Med Wochenschr; 1972 Jan; 102(3):88-94. PubMed ID: 4551909
    [No Abstract]   [Full Text] [Related]  

  • 25. L-Dopa therapy of Parkinson's disease. (A review of the preliminary experience at West Virginia University).
    Gutmann L; Martin JD; Gutrecht JA
    W V Med J; 1970 Apr; 66(4):109-11. PubMed ID: 5264660
    [No Abstract]   [Full Text] [Related]  

  • 26. Dopa in Parkinson's disease.
    Rosenberg H
    N Engl J Med; 1969 Mar; 280(13):730. PubMed ID: 5766091
    [No Abstract]   [Full Text] [Related]  

  • 27. An analysis of L-dopa-induced dyskinesias in 152 cases of Parkinson's disease.
    Mones RJ; Elizan TS; Siegel GJ
    Neurology; 1970 Apr; 20(4):405-6. PubMed ID: 5535050
    [No Abstract]   [Full Text] [Related]  

  • 28. The role of a dihydromorphanthridine derivative in Parkinson's patients treated with L-dopa. A preliminary report.
    Wycis HT
    Confin Neurol; 1972; 34(2):130-5. PubMed ID: 4666056
    [No Abstract]   [Full Text] [Related]  

  • 29. [New methods for measurement of the tremor and rigidity in patients with Parkinson's disease treated with L-Dopa].
    Paci A; Freddi A; Barba C
    Riv Neurol; 1973; 43(1):15-39. PubMed ID: 4698011
    [No Abstract]   [Full Text] [Related]  

  • 30. [Disulfiram and L-dopa in patients with Parkinson's syndrome and in torsion dystonia].
    Serrano PA; Irigoyen M
    Prensa Med Mex; 1972; 37(7):246-50. PubMed ID: 4646433
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].
    Lombardo L; de la Garza R; Ivan-Reynoso G
    Arch Invest Med (Mex); 1974; 5(2):105-16. PubMed ID: 4433198
    [No Abstract]   [Full Text] [Related]  

  • 32. Amino acid and dopa levels in plasma and urine from L-dopa-treated patients with Parkinson's disease.
    Hare TA; Vanna S; Beasley B; Chambers R; Vogel WH
    J Lab Clin Med; 1971 Feb; 77(2):319-25. PubMed ID: 5540775
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment of Parkinson's disease with L-dopa].
    Guglielmi L; Vecchi L
    Clin Ter; 1970 May; 53(3):259-69. PubMed ID: 4917328
    [No Abstract]   [Full Text] [Related]  

  • 34. [L-dopa therapy of Parkinson's syndrome. Comparison of pure L-dopa and the combination preparation L-dopa and decarboxylase inhibitor].
    Görlich J; Markus E
    Dtsch Med Wochenschr; 1972 Aug; 97(34):1246-8. PubMed ID: 5048316
    [No Abstract]   [Full Text] [Related]  

  • 35. Dihydroxyphenylalanine (DOPA) in plasma during dopa treatment of patients with Parkinson's disease.
    Tyce GM; Muenter MD; Owen CA
    Mayo Clin Proc; 1970 Jun; 45(6):438-43. PubMed ID: 5425103
    [No Abstract]   [Full Text] [Related]  

  • 36. [Biochemical bases for the treatment of Parkinson's syndrome with L-dopa].
    Pletscher A; Bartholini G; Gey KF; Jenni A
    Schweiz Med Wochenschr; 1970 May; 100(19):797-804. PubMed ID: 4924275
    [No Abstract]   [Full Text] [Related]  

  • 37. [Clinical remarks on the action of intravenous and oral levo-dopa in the treatment of Parkinson's disease (135 cases)].
    Fasano VA; Urciuoli R; Broggi G; Cannella M; Lombard GF
    Neurochirurgie; 1970; 16(2):171-8. PubMed ID: 5451127
    [No Abstract]   [Full Text] [Related]  

  • 38. [Therapeutic effects of L-dopa and trihexyphenidyl in Parkinson's disease--an examination by a double blind method].
    Hirayama K; Uono M; Nakanishi T; Kato N; Nagao Y
    Shinkei Kenkyu No Shimpo; 1971; 15(1):267-85. PubMed ID: 4937721
    [No Abstract]   [Full Text] [Related]  

  • 39. [Abnormal movements observed during treatment of Parkinson's disease with L-dopa].
    Sigwald J; Raymondeaud C
    Rev Neurol (Paris); 1970 Feb; 122(2):103-12. PubMed ID: 4397165
    [No Abstract]   [Full Text] [Related]  

  • 40. L-dopa therapy in Parkinson's disease.
    Lipman IJ
    Va Med Mon (1918); 1971 May; 98(5):242-8. PubMed ID: 4931138
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.